EDITORIAL
Published on 10 Aug 2026
Editorial: EGFR-targeted therapy in lung cancer: unraveling molecular regulation, overcoming resistance, and advancing precision clinical practice
doi 10.3389/fmolb.2026.1936450
- 415 views
- Frontiers in Molecular Biosciences
- Molecular Diagnostics and Therapeutics
- Research Topics
- EGFR-Targeted Therapy in Lung Cancer: Unraveling Molecular Regulation, Overcoming Resistance, and Advancing Precision Clinical Practice
EGFR-Targeted Therapy in Lung Cancer: Unraveling Molecular Regulation, Overcoming Resistance, and Advancing Precision Clinical Practice
4,438
Total downloads
34k
Total views and downloads
Articles
SYSTEMATIC REVIEW
Published on 16 Jul 2026
Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis
doi 10.3389/fonc.2026.1832920
- 1,367 views
ORIGINAL RESEARCH
Published on 25 Jun 2026
Body mass index and fasting insulin predict survival and EGFR–TKI benefit in Stage IV lung adenocarcinoma
doi 10.3389/fonc.2026.1742177
- 799 views
ORIGINAL RESEARCH
Published on 22 Jun 2026
Association between radiotherapy timing and intracranial outcomes in EGFR-mutant NSCLC with brain metastases treated with EGFR-TKIs
doi 10.3389/fonc.2026.1708604
- 872 views
ORIGINAL RESEARCH
Published on 19 May 2026
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC
doi 10.3389/fonc.2026.1827867
- 1,444 views
CASE REPORT
Published on 12 May 2026
Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids
doi 10.3389/fonc.2026.1742943
- 1,201 views
ORIGINAL RESEARCH
Published on 24 Apr 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC
doi 10.3389/fmolb.2026.1822285
- 1,370 views
- 2 citations
SYSTEMATIC REVIEW
Published on 10 Apr 2026
Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies
doi 10.3389/fimmu.2026.1787310
- 1,882 views
CASE REPORT
Published on 26 Mar 2026
Case Report: Olaparib combined with temozolomide and atezolizumab in a case of BRCA2-mutated small-cell transformation of lung adenocarcinoma
doi 10.3389/fonc.2026.1767999
- 1,260 views
- 2 citations
CASE REPORT
Published on 25 Mar 2026
Case Report: SMARCA4-deficient non-small cell lung cancer — effective local control with radiotherapy and emergence of a targetable EGFR mutation
doi 10.3389/fonc.2026.1724204
- 2,088 views
CASE REPORT
Published on 12 Mar 2026
FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report
doi 10.3389/fonc.2026.1780493
- 1,522 views
ORIGINAL RESEARCH
Published on 03 Mar 2026
CD73 expression as a resistance mechanism in advanced EGFR-mutated non-small cell lung cancer
doi 10.3389/fonc.2026.1755595
- 1,121 views
